person applying medical cream to hand

Treatment of Severe Atopic Eczema Trial (project complete)

A Randomised Controlled Trial Assessing the Effectiveness, Safety and Cost-effectiveness of Methotrexate versus Ciclosporin in the Treatment of Severe Atopic Eczema in Children: The TREatment of Severe Atopic Eczema Trial (TREAT)

Treat logo, Hand applying cream and artist impression of skin struture

About the project

The TREAT (TREatment of Severe Atopic Eczema Trial) study was a national multi-centre randomized controlled trial that assessed the effectiveness, safety, and cost-effectiveness of methotrexate versus ciclosporin in treating severe atopic eczema in children.

Led by Professor Carsten Flohr, Consultant Paediatric Dermatologist at St John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation Trust, the trial aimed to recruit 102 patients aged 2-16 years requiring systemic treatment. Participants were randomly allocated to receive either methotrexate or ciclosporin for 9 months, followed by a 6-month follow-up period to evaluate short- and long-term effectiveness as well as the safety profile of both drugs. TREAT also addressed gaps in current knowledge regarding how these medicines reduce skin inflammation and itch.

Recruitment has now closed

The recruitment process is now complete. You can read through this site to understand the study and its results.

Study overview video

Find out about the trial from Prof Carsten Flohr. Understand the reason for the trial, how it was conducted and the results.

Summer and Stephanie’s experience

Find out about Summer and her mum Stephanie’s experience with the TREAT trial. With interviews from Prof Carsten Flohr and Charlotte Walker.

Hospital departments taking part

Hospital departments taking part

The study will take part in Dermatology Departments across the country. To see if your hospital is taking part in this study please go to recruiting centres.

Study funder

Study funder

The study will take part in Dermatology Departments across the country. To see if your hospital is taking part in this study please go to recruiting centres.

Study organiser

Study organiser

The study will take part in Dermatology Departments across the country. To see if your hospital is taking part in this study please go to recruiting centres.

Study review

Study review

The study has been reviewed by a research ethics committee, who have agreed the study is being conducted in a correct and appropriate manner. The study has also been approved by the Medicines & Healthcare products Regulatory Agency (MHRA).

Infographic titled "Treatment of severe atopic dermatitis in children and young people trial (TREAT)" by Flohr et al., BJD 2023. Population: Multicentre, parallel group, assessor-blinded clinical trial 13 centres across the UK and Ireland Participants aged 2-16, n=103 Inclusion criteria: severe atopic dermatitis (AD) unresponsive to potent topical treatment Intervention: Oral ciclosporin (CyA, 4mg/kg/day), n=52 Oral methotrexate (MTX, 0.4mg/kg/week), n=51 36 weeks on treatment, 24 weeks follow-up Objectives: Change in disease severity (o-SCORAD) 0-12 weeks Time to first significant flare post-treatment cessation Disease severity 0-60 weeks (EASI, o-SCORAD, IGA, POEM) Impact on quality of life (QoL) 0-60 weeks (CDLQI, DFI) Treatment safety Findings: Greater improvement in disease severity with CyA vs. MTX at week 12 MTX superior to CyA by week 36, continuing off treatment until week 60 Higher proportion of participants on CyA reporting significant flare post-treatment (48% CyA vs. 35% MTX) Number of adverse effects comparable between treatment arms No significant blood-based safety signals Graph: Mean profile plot for EASI score from baseline up to week 60, comparing CyA and MTX. Points at week 12, 24, 36, and 60 indicate statistical significance (P < 0.05). Conclusions: CyA and MTX are effective treatments over a 36-week period CyA works faster initially, but more sustained treatment response seen with MTX, even after treatment cessation. Logos: TREAT logo, British Association of Dermatologists (BAD) logo, and BJD (British Journal of Dermatology) logo.

The British Journal of Dermatology

Trial summary and frequently asked questions

Funded by National Institute for Health Research's Efficacy and Mechanism Evaluation (EME) Programme

national institute for health research and medical research council logos

Contact us

Get in touch to find out more about the TREAT trial

Telephone 1517958760
Address

Medicines for Children Clinical Trials Unit
Clinical Trials Research Centre
University of Liverpool
Institute of Child Health
Alder Hey Children’s NHS Foundation Trust
Liverpool, L12 2AP